- Medical device - CE marked
The future of cancer diagnostics - clinically proven
Revolutionary ctDNA technology with over 95% sensitivity and specificity. Detects recurrence 6 months before X-ray. An innovation from Simsen Diagnostics and Durus Medicus AB, with support from the University of Gothenburg.
Trusted by healthcare providers across Sweden
- Health center
- Hospital
- Specialist
From today's challenges to tomorrow's solutions
Current cancer diagnostics have significant limitations. ctDNA technology addresses these challenges.
Current diagnostics
- Symptom-based detection - often too late
- Screening with overdiagnosis and false positives/negatives
- Limited for young patients
- Late detection of relapse and treatment resistance
The ctDNA solution
- Very precise blood test - over 95% accuracy
- Can be used for all cancers - universal technology
- Easy to perform - just a blood test
- Detects recurrence 6 months before X-ray
- Revolutionary technology
How ctDNA diagnostics work
A revolutionary method that searches for circulating tumor DNA in the blood
The genetic profile of the tumor is analyzed to identify specific biomarkers that can be detected in the blood.
A standard blood sample is taken from the patient – no complicated preparation or invasive procedures are required.
Advanced technology searches for the smallest traces of cancer DNA circulating freely in the blood.
Benefits of ctDNA screening
Lorem ipsum elementum dignissim lacus nulla sit nibh nec suspendisse porttitor maecenas arcu turpis lectus.
Lorem ipsum ligula tellus
Early detection
Detects recurrence 3-6 months faster than traditional X-ray
Early detection
High precision
Sensitivity over 95%, specificity over 99% for optimal reliability
High precision
Fast results
Digital test answers within 24-48 hours via secure login
Fast results
Safe method
Minimally invasive - only a simple blood test is required
Safe method
- Lorem ipsum
The science behind ctDNA
All cells in the body release small fragments of their DNA when they die. This is called cell-free DNA and circulates freely in the blood for a short time.
When tumor cells die, their DNA is released and mixes with the body’s normal DNA. The part of the cell-free DNA that comes from the tumor is called ctDNA (circulating tumor DNA).
Because ctDNA carries the same genetic changes as the tumor itself, a blood test that measures ctDNA can provide valuable information to:
- Follow the development of the disease in real time
- Detecting early recurrences months before radiology
- Identify changes that affect treatment
- Tailoring personalized cancer care
All tumors are as unique as a fingerprint. That’s why a customized test is performed for your specific form of cancer, developed by experienced specialists.
Book your blood test today.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Check-up
Lorem ipsum elementum
Total Markers Tested: 15
Body Areas Covered: 5
50,000 SEK 60,000 SEK
- Lorem ipsum
Important medical information:
Lorem ipsum in tristique fringilla fames feugiat enim nibh sed pharetra suscipit consectetur sit et consectetur felis massa enim habitant est mauris vestibulum ipsum metus eget eleifend faucibus morbi quisque feugiat ut ac pretium ultrices feugiat elit id ultrices nulla.
This screening does not replace regular medical visits or traditional diagnostics
Results should always be discussed with your treating physician
We cannot guarantee 100% safety in all medical cases
Diagnoses are made only by doctors - not by this test
ctDNA analysis is a complement to traditional cancer diagnostics
Simsen Diagnostics
Innovative diagnostic development
Hard Doctor AB
- Lorem ipsum
Unique collaboration
Combines clinical expertise from the University of Gothenburg with innovative diagnostic development for optimal patient benefit
With support from
University of Gothenburg | Sahlgrenska Academy
- Lorem ipsum
Testimonial
Lorem ipsum commodo
Dr. Kamuran Inci
Chief Physician
University of Gothenburg
“Just as obvious as ChatGPT became in 2 years, ctDNA will be an obvious and natural part of cancer care within 2-5 years.”
Rochelle Rodriguez-Crist
Product Applications Director
University of Switzerland
Lorem ipsum in purus lobortis sodales tincidunt pretium amet semper imperdiet senectus sit non suscipit.
Success belongs to those who dare to be first.
Lorem ipsum ultrices adipiscing urna dolor gravida integer risus adipiscing.